Yun Hee Jin, Kim Su-Jin, Han Kwang Eon, Choi Eun Jung, Lee Ji-Eun
Department of Ophthalmology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
Front Pharmacol. 2025 May 13;16:1547236. doi: 10.3389/fphar.2025.1547236. eCollection 2025.
Linezolid is a useful second-line medication for the treatment of tuberculosis that is resistant to multiple drugs. However, long-term therapy can cause side effects, such as optic neuropathy. We describe three cases of progressive painless bilateral visual loss in patients taking long-term linezolid therapy for multidrug-resistant and extensively drug-resistant tuberculosis. We reviewed the literatures and identified 58 cases of linezolid optic neuropathy. Discontinuation of linezolid resulted in a marked improvement in vision, however it was not complete in all patients. Knowledge of visual monitoring of patients undergoing long-term linezolid therapy is important for physicians and ophthalmologists.
利奈唑胺是治疗耐多药结核病的一种有用的二线药物。然而,长期治疗可能会引起副作用,如视神经病变。我们描述了3例长期服用利奈唑胺治疗耐多药和广泛耐药结核病的患者出现进行性双侧无痛性视力丧失的病例。我们查阅了文献,确定了58例利奈唑胺所致视神经病变病例。停用利奈唑胺后视力有显著改善,但并非所有患者都完全恢复。对于内科医生和眼科医生来说,了解对接受长期利奈唑胺治疗的患者进行视力监测非常重要。